-
AbelZeta Pharma’s CAR-T Therapy C-CAR031 Receives Implicit Approval for Clinical Study in China
•
Sino-US biotechnology company AbelZeta Pharma Inc., operating in Rockville, Maryland, and Shanghai, China, has received implicit approval for its autologous armored GPC3-targeted chimeric antigen receptor (CAR) T cell therapy, C-CAR031, developed by its subsidiary, Shanghai Cellular Biopharmaceutical Group Ltd. The therapy is intended for the treatment of GPC3+ advanced or…
-
AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China
•
AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China, has announced an updated global collaboration and licensing agreement with Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ). According to the revised agreement, Janssen will now secure commercialization rights to CAR-T therapies C-CAR039…
-
AbelZeta and AstraZeneca Team Up for Co-Development of GPC3-Targeted CAR-T Therapy
•
AbelZeta Pharma Inc., a Sino-U.S. biotech firm based in Rockville, Maryland, and Shanghai, has announced a co-development agreement with AstraZeneca (AZ, NASDAQ: AZN) for its C-CAR031 chimeric antigen receptor (CAR) T cell therapy. C-CAR031 is an autologous, armored CAR-T therapy specifically targeting GPC3, currently under development for hepatocellular carcinoma (HCC).…
